证券代码：688426 证券简称：康为世纪 公告编号：2026-011 江苏康为世纪生物科技股份有限公司 关于自愿披露九项呼吸道病原体核酸检测试剂盒 （荧光 PCR 法）获得三类医疗器械注册证的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，江苏康为世纪生物科技股份有限公司（以下简称"公司"）全资子公司 江苏健为诊断科技有限公司（以下简称"健为诊断"）自主研发的九项呼吸道病原 体核酸检测试剂盒（荧光 PCR 法）收到国家药品监督管理局颁发的 III 类《医疗 器械注册证（体外诊断试剂）》，具体情况如下： | 注册人名称 | 江苏健为诊断科技有限公司 | | --- | --- | | 注册人住所 | 泰州市药城大道五期厂房G131号楼3层 | | 生产地址 | 泰州市医药高新区泽兰路18号-B栋一层，D栋一、二、三层，E | | | 栋三层（委托生产） | | 产品名称 | 九项呼吸道病原体核酸检测试剂盒（荧光PCR法） | | | 本试剂盒用于体外定性检测人咽拭子样本中的甲型流感病毒 （Flu A）、乙型流感病 ...

Financial Performance Summary - The company achieved operating revenue of 193.05 million yuan, representing a year-on-year increase of 53.36% [3] - The total profit was -107.32 million yuan, with a net profit attributable to the parent company of -103.28 million yuan, and a net profit excluding non-recurring gains and losses of -134.82 million yuan, all showing a reduction in losses compared to the previous year [3] - The total assets at the end of the reporting period were 1.51 billion yuan, a decrease of 6.65% from the beginning of the period, while the equity attributable to the parent company was 1.36 billion yuan, down 7.54% [4] Business Operations and Factors Influencing Performance - The company focused on consolidating existing businesses while actively exploring new ones, with rapid growth in technology service businesses such as gene sequencing and gene synthesis driving revenue growth [5] - The company improved operational efficiency, controlling expenses effectively despite significant revenue growth, and reduced R&D expenses by optimizing resource allocation and focusing on advantageous projects [5] Changes in Key Financial Metrics - The company experienced a significant reduction in operating profit and total profit compared to the previous year, primarily due to increased revenue from new technology services and effective expense management [6]

Group 1 - The core viewpoint of the article is that Kangwei Century announced a significant increase in its total operating revenue for the year 2025, reaching 1,930.482 million yuan, which represents a year-on-year growth of 53.36% [2]

Core Viewpoint - Kangwei Century (688426.SH) reported a significant increase in revenue for the year 2025, driven by growth in technology services such as gene sequencing and synthesis, despite facing intense market competition [1] Financial Performance - The company achieved operating revenue of 193.05 million yuan, representing a year-on-year increase of 53.36% [1] - The net profit attributable to the parent company was -103.28 million yuan, while the net profit after deducting non-recurring gains and losses was -134.82 million yuan, both showing a reduction in losses compared to the previous year [1] Business Strategy - The management focused on consolidating existing businesses while actively exploring new opportunities, contributing to the revenue growth [1] - The company improved operational efficiency, controlling expenses effectively despite significant revenue growth [1] Research and Development - R&D expenditures decreased year-on-year as the company optimized resource allocation and focused on advantageous projects to enhance R&D efficiency [1]

Financial Performance - The company achieved total operating revenue of 193.05 million yuan, a year-on-year increase of 53.36%[3] - The total profit for the period was -107.32 million yuan, and the net profit attributable to the parent company was -103.28 million yuan, both showing a reduction in losses compared to the previous year[5] - The basic earnings per share were -0.94 yuan, an improvement from -1.41 yuan in the previous year[3] Assets and Equity - The company's total assets at the end of the reporting period were 1,510.54 million yuan, a decrease of 6.65% from the beginning of the period[6] - The equity attributable to the parent company was 1,355.24 million yuan, down 7.54% from the beginning of the period[6] Business Growth and Strategy - The company focused on the rapid growth of technology service businesses such as gene sequencing and gene synthesis, which significantly contributed to revenue growth[7] - Operating efficiency improvements allowed the company to control expenses effectively, leading to a significant reduction in losses despite increased revenue[8] - Research and development expenses were optimized, resulting in a year-on-year decrease while focusing on advantageous projects[7] - The company emphasizes the importance of market-oriented resource allocation to enhance R&D efficiency[7] Financial Reporting - Investors are advised to note that the financial data presented are preliminary and unaudited, with final figures to be confirmed in the official annual report[9]

Core Viewpoint - Jiangsu Kangwei Century Biotechnology Co., Ltd. has announced a change in its continuous supervision sponsor representative from Yang Ling to Wang Wei, ensuring the orderly continuation of the supervision work by CITIC Securities [1][2]. Group 1 - CITIC Securities is the sponsor institution for the company's initial public offering (IPO) and listing project on the Shanghai Stock Exchange's Sci-Tech Innovation Board [1]. - The continuous supervision period is set to last until December 31, 2025 [1]. - Wang Wei has been appointed to replace Yang Ling as the sponsor representative, while Jiang Hao remains in the role, ensuring no disruption in the supervision process [1]. Group 2 - The board of directors expressed gratitude for Yang Ling's contributions during the continuous supervision period of the IPO project [2]. - Wang Wei holds a master's degree and is currently a senior vice president at CITIC Securities Investment Banking Management Committee [3]. - Wang Wei has been involved in several major projects, including the IPOs of Ruili Kemi and Kangwei Century, among others [3].

Core Viewpoint - Jiangsu Kangwei Century Biotechnology Co., Ltd. has announced a change in its continuous supervision sponsor representative due to the work transition of the previous representative, Yang Ling, ensuring the orderly continuation of supervision work [1][2]. Group 1: Company Announcement - The company received a letter from CITIC Securities regarding the replacement of the continuous supervision sponsor representative [1]. - Yang Ling and Jiang Hao were originally appointed as the sponsor representatives for the company's initial public offering (IPO) project, with supervision lasting until December 31, 2025 [1]. - Wang Wei has been appointed to replace Yang Ling as the new sponsor representative, alongside Jiang Hao, to continue fulfilling the relevant duties and obligations of continuous supervision [1]. Group 2: Acknowledgment - The company's board expressed sincere gratitude for Yang Ling's contributions during the continuous supervision period of the IPO project [2]. Group 3: New Sponsor Representative Profile - Wang Wei holds a master's degree and currently serves as a senior vice president of the Investment Banking Management Committee at CITIC Securities [3]. - He has been involved in several major projects, including the IPOs of Ruili Kemi and Kangwei Century, as well as other financing and acquisition projects [3].

Core Viewpoint - The announcement by Kangwei Century regarding the change in the lead sponsor representative for its IPO project on the Shanghai Stock Exchange's Sci-Tech Innovation Board is a significant operational update for the company [2] Group 1: Company Announcement - Kangwei Century announced that CITIC Securities is the sponsor for its initial public offering (IPO) and listing project [2] - The original designated sponsor representatives, Yang Ling and Jiang Hao, were responsible for the ongoing supervision until December 31, 2025 [2] - Due to a work change, Yang Ling will no longer serve as the lead representative for the ongoing supervision project, and Wang Wei has been appointed to take over this role [2]

中信证券作为公司首次公开发行股票并在上海证券交易所科创板上市项目（以下简 称"首次公开发行股票并上市项目"）的保荐机构，原委派保荐代表人杨凌先生、姜浩先 生负责公司持续督导工作，持续督导期至 2025 年 12 月 31 日。鉴于杨凌先生工作变动 原因，不再担任公司首次公开发行股票持续督导项目的保荐代表人，为保证持续督导工 作的有序进行，中信证券现委派王伟先生（简历详见附件）接替杨凌先生担任公司的保 荐代表人，继续履行持续督导的相关职责和义务。 本次保荐代表人更换后，公司持续督导保荐代表人为王伟先生、姜浩先生，本次更 换不影响中信证券对公司的持续督导工作。 公司董事会对杨凌先生在公司首次公开发行股票并上市项目持续督导期间做出的 贡献表示衷心感谢！ 证券代码：688426 证券简称：康为世纪 公告编号：2026-009 江苏康为世纪生物科技股份有限公司 关于更换持续督导保荐代表人的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，江苏康为世纪生物科技股份有限公司（以下简称"康为世纪"或"公司"）收到 中信证券股份有限 ...

Core Viewpoint - Jiangsu Kangwei Century Biotechnology Co., Ltd. announced the retirement of its internal audit department head, Mr. Tang Yufeng, who will no longer hold any position in the company after his departure [1]. Group 1 - The board of directors received a written resignation report from Mr. Tang Yufeng due to retirement [1]. - Mr. Tang's resignation will take effect upon delivery to the board of directors, and it will not impact the company's normal operations [1]. - The board expressed gratitude for Mr. Tang's contributions during his tenure [1].